DK1759700T3 - Anvendelse af en PDE5-inhibitor til behandling og forebyggelse af hypopigmentlidelser - Google Patents

Anvendelse af en PDE5-inhibitor til behandling og forebyggelse af hypopigmentlidelser

Info

Publication number
DK1759700T3
DK1759700T3 DK04019695T DK04019695T DK1759700T3 DK 1759700 T3 DK1759700 T3 DK 1759700T3 DK 04019695 T DK04019695 T DK 04019695T DK 04019695 T DK04019695 T DK 04019695T DK 1759700 T3 DK1759700 T3 DK 1759700T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
pde5 inhibitor
hypopigmentation disorders
disorders
Prior art date
Application number
DK04019695T
Other languages
Danish (da)
English (en)
Inventor
Heidemarie Peuker
Original Assignee
Switch Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Switch Biotech Llc filed Critical Switch Biotech Llc
Application granted granted Critical
Publication of DK1759700T3 publication Critical patent/DK1759700T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04019695T 2004-08-19 2004-08-19 Anvendelse af en PDE5-inhibitor til behandling og forebyggelse af hypopigmentlidelser DK1759700T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04019695A EP1759700B1 (en) 2004-08-19 2004-08-19 Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders

Publications (1)

Publication Number Publication Date
DK1759700T3 true DK1759700T3 (da) 2009-10-12

Family

ID=34926226

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04019695T DK1759700T3 (da) 2004-08-19 2004-08-19 Anvendelse af en PDE5-inhibitor til behandling og forebyggelse af hypopigmentlidelser

Country Status (6)

Country Link
EP (1) EP1759700B1 (es)
JP (1) JP4904268B2 (es)
AT (1) ATE438403T1 (es)
DE (1) DE602004022463D1 (es)
DK (1) DK1759700T3 (es)
ES (1) ES2330934T3 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834505A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transdermales therapeutisches System zur Anwendung von Sildenafil
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
HUP0401544A2 (hu) * 2001-03-02 2004-12-28 Bristol-Myers Squibb Company Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1492567A1 (en) * 2002-03-06 2005-01-05 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics in cancer treatment
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
WO2004044234A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004096222A1 (en) * 2003-04-30 2004-11-11 Switch Biotech Ag Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders

Also Published As

Publication number Publication date
ES2330934T3 (es) 2009-12-17
JP2008509944A (ja) 2008-04-03
EP1759700A1 (en) 2007-03-07
EP1759700B1 (en) 2009-08-05
JP4904268B2 (ja) 2012-03-28
DE602004022463D1 (de) 2009-09-17
ATE438403T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
WO2006120176A3 (en) Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
DK1928850T3 (da) Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
EP1761532A4 (en) AMINOCYCLOHEXANES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1756074A4 (en) 1,2,4-OXADIAZOLE DERIVATIVES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV IN THE TREATMENT OR PREVENTION OF DIABETES
EA200801118A1 (ru) Способ ингибирования flt3 киназы
DE602005022427D1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
EP1756106A4 (en) CYCLOHEXYLALANINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
NL1028761A1 (nl) Dipeptidylpeptidase-IV remmers.
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
DK1753748T3 (da) Prolinderivater og deres anvendelse som dipeptidyl-peptidase-IV-inhibitorer
LTC1412357I2 (lt) Beta-amino tetrahidroimidazo(1,2-a)pirazinai ir tetrahidrotrazolo(4,3-A)pirazinai kaip dipeptidilpeptidazės inhibitoriai, skirti diabeto gydymui arba prevencijai
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
IL180871A0 (en) Substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase iv
EP1753428A4 (en) INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
DK1703909T3 (da) 1-benzoyl-piperazinderivater som glycinoptagelsesinhibitorer til behandling af psykoser
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
DE602004010206D1 (de) Dipeptidyl Peptidase Inhibitoren.
DK1919466T3 (da) Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
DK1723135T3 (da) Kendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som pde4-inhibitorer
EP1786428A4 (en) PDE5 INHIBITOR COMPOSITIONS AND METHOD FOR TREATING DISEASE
PL1709030T3 (pl) Pochodne imidu kwasu indolilomaleinowego
NO20092145L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon
AP2005003227A0 (en) Synergistic combination of an alpha-2-delta ligandand a PDEV inhibitor for use in the treatment of pain.
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.